STAT+: Alnylam raises guidance as sales of heart drug match expectations

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we have a deep probe into Moderna’s travails from STAT’s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic regulation, and the Trump administartion is trying to fast-track cheaper biosimilars. 

The need-to-know this morning

• A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro and Zepbound brand names, delivered $10.1 billion in third-quarter sales. Tirzepatide’s quarterly sales surpassed the $8.1 billion in sales from Merck’s cancer immunotherapy blockbuster Keytruda for the first time. 

• More earnings from Bristol Myers Squibb, Biogen, Insmed, Apellis, and Astellas. 

Moderna’s mRNA empire stumbles amid politics, retrenchment

Once seemingly on top of the world, Moderna now faces a brutal reset.

Continue to STAT+ to read the full story…